10/01/2012
Presidio Pharmaceuticals completes PPI-668 Phase 1a study on hepatitis C
PPI-668 is a potent, pan-genotypic second-generation hepatitis C virus NS5A inhibitor.
Read the press release here.
Presidio Pharmaceuticals, Inc.
http://www.presidiopharma.com/
Share this page
DISCLAIMER
The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.
More...
